A SIMPLE KEY FOR HEMGENIX UNVEILED

Amount of qualified clients: CDEC reviewed the uncertainty in the quantity of sufferers with reasonably critical to severe hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some clients who are labeled as owning moderate or reasonable illness can have a critical bleeding phenotype,